Deferiprone

Deferiprone is indicated for the treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate. 2).

). Absolute Neutrophil Counts The absolute neutrophil count (ANC) should be measured before starting FERRIPROX or FERRIPROX MR therapy and monitored weekly on therapy (see 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS, Hematologic section above).

Product Monograph Master Template Template Date:

September 2020 FERRIPROX deferiprone, FERRIPROX MR deferiprone Page 14 of 54 Hepatic function Hepatic status should be evaluated prior to initiating FERRIPROX or FERRIPROX MR treatment. Serum ALT values should be monitored periodically during therapy with FERRIPROX or FERRIPROX MR.

In patients with hepatic impairment, hepatic enzymes should be monitored periodically. Special care must be taken to ensure that iron chelation in patients with hepatitis C is optimal. In these patients careful monitoring of liver enzymes and of liver histology is recommended.

Plasma Zinc concentration Monitoring of plasma Zn2+ concentration, and supplementation in case of a deficiency, is recommended. 5 times the maximum recommended dose, but have also been observed with standard doses of deferiprone. The neurological disorders regressed after FERRIPROX discontinuation (

Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. 2).